Skip to main content
Erschienen in: Clinical Drug Investigation 5/2005

01.05.2005 | Original Research Article

Taste Comparisons for Lansoprazole Strawberry-Flavoured Delayed-Release Orally Disintegrating Tablet and Ranitidine Peppermint-Flavoured Syrup in Children

verfasst von: Dr Vasundhara Tolia, Cong Han, Janine D. North, Fouad Amer

Erschienen in: Clinical Drug Investigation | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Objective: To compare the flavour and taste preferences of two acid-inhibitory therapies in children.
Subjects and setting: 104 (52 male and 52 female) healthy children aged 6–11 years participated in this phase IV single-centre, taste-test study after parental consent was obtained.
Methods: Children were divided into two groups based upon age: group 1 included children aged 6–8 years and group 2 included children aged 9–11 years. Within each group an equal number of male and female subjects were recruited. Within each of the four strata defined by group and sex, an equal number of subjects were randomised to taste the strawberry-flavoured lansoprazole 15mg orally disintegrating tablet or the ranitidine 75mg/5mL peppermint-flavoured syrup samples in position 1. In group 1, the lansoprazole 15mg delayed-release orally disintegrating tablet was dispersed in 5mL of water, while in group 2, children gently rolled the tablet on the tongue until dissolution, before swallowing the particles. Children given the dose of lansoprazole dispersed in water (group 1) and the ranitidine dose (groups 1 and 2) were to taste it, swish it in their mouth for up to 10 seconds, and then swallow it. Children were given ambient temperature water and unsalted crackers to cleanse the palate during a 10-minute break between tastings.
Main outcome measures: After each tasting, children rated their degree of liking on a five-point facial hedonic scale (5 = like very much, 1 = dislike very much). Product preference was recorded after the tasting of both samples.
Results: Among group 1 and group 2 participants, 86.5% (45/52) and 90.4% (47/ 52) of children, respectively, ‘liked’ (‘like a little’ or ‘like very much’) the strawberry-flavoured lansoprazole orally disintegrating tablet. The proportion of children who ‘liked’ the peppermint-flavoured ranitidine syrup was lower than the proportion who liked lansoprazole, and the proportions were similar between the groups: 13.5% (7/52) in group 1 and 9.6% (5/52) in group 2. Children in both groups preferred the strawberry-flavoured lansoprazole delayed-release orally disintegrating tablet: 92% (95% CI 81.1, 97.8; p < 0.001) of those in group 1 and 98% (95% CI 89.7, 100.0; p < 0.001) of those in group 2.
Conclusion: After tasting both products, >92% of children aged from 6–11 years preferred the strawberry-flavoured lansoprazole delayed-release orally disintegrating tablet, either dissolved in a small amount of water or allowed to dissolve on the tongue, over the peppermint-flavoured ranitidine syrup.
Literatur
1.
Zurück zum Zitat Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during infancy: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997; 151: 569–72PubMedCrossRef Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during infancy: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997; 151: 569–72PubMedCrossRef
2.
Zurück zum Zitat Nelson SP, Chen EH, Syniar GM, et al. Pediatric Practice Research Group. Prevalence of symptoms of gastroesophageal reflux during childhood. Arch Pediatr Adolesc Med 2000; 154: 150–4PubMed Nelson SP, Chen EH, Syniar GM, et al. Pediatric Practice Research Group. Prevalence of symptoms of gastroesophageal reflux during childhood. Arch Pediatr Adolesc Med 2000; 154: 150–4PubMed
3.
Zurück zum Zitat Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32Suppl. 2: S1–S31PubMedCrossRef Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32Suppl. 2: S1–S31PubMedCrossRef
4.
Zurück zum Zitat Gremse DA, Donnelly JR, Kukulka MJ, et al. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther 2004; 19: 1211–5PubMedCrossRef Gremse DA, Donnelly JR, Kukulka MJ, et al. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther 2004; 19: 1211–5PubMedCrossRef
5.
Zurück zum Zitat Freston JW, Chiu YL, Mulford DJ, et al. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003; 17: 361–7PubMedCrossRef Freston JW, Chiu YL, Mulford DJ, et al. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003; 17: 361–7PubMedCrossRef
6.
Zurück zum Zitat Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003; 67: 1–5PubMedCrossRef Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003; 67: 1–5PubMedCrossRef
7.
Zurück zum Zitat Tolia V, Johnston G, Stolle J, et al. Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup in children aged between 5–11 years. Pediatr Drugs 2004; 6(2): 127–31CrossRef Tolia V, Johnston G, Stolle J, et al. Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup in children aged between 5–11 years. Pediatr Drugs 2004; 6(2): 127–31CrossRef
8.
Zurück zum Zitat Matsui D, Lim R, Tschen T, et al. Assessment of the palatability of β-lactamase-resistant antibiotics in children. Arch Pediatr Adolesc Med 1997; 151: 599–602PubMedCrossRef Matsui D, Lim R, Tschen T, et al. Assessment of the palatability of β-lactamase-resistant antibiotics in children. Arch Pediatr Adolesc Med 1997; 151: 599–602PubMedCrossRef
9.
Zurück zum Zitat Matsui D, Barron A, Rieder M. Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers. Ann Pharmacol Ther 1996; 30: 586–8 Matsui D, Barron A, Rieder M. Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers. Ann Pharmacol Ther 1996; 30: 586–8
10.
Zurück zum Zitat Angelilli ML, Toscani M, Matsui DM, et al. Palatability of oral antibiotics among children in an urban primary care center. Arch Pediatr Adolesc Med 2000; 154: 267–70PubMed Angelilli ML, Toscani M, Matsui DM, et al. Palatability of oral antibiotics among children in an urban primary care center. Arch Pediatr Adolesc Med 2000; 154: 267–70PubMed
11.
Zurück zum Zitat Uhari M, Eskelinen L, Jokisalo J. Acceptance of antibiotic mixtures by infants and children. Eur J Clin Pharmacol 1986; 30: 503–4PubMedCrossRef Uhari M, Eskelinen L, Jokisalo J. Acceptance of antibiotic mixtures by infants and children. Eur J Clin Pharmacol 1986; 30: 503–4PubMedCrossRef
12.
Zurück zum Zitat Keast RS, Breslin PA. Modifying the bitterness of selected oral Pharmaceuticals with cation and anion series of salts. Pharm Res 2002; 19: 1019–26PubMedCrossRef Keast RS, Breslin PA. Modifying the bitterness of selected oral Pharmaceuticals with cation and anion series of salts. Pharm Res 2002; 19: 1019–26PubMedCrossRef
13.
Zurück zum Zitat Temple ME, Nahata MC. Comparative palatability of 22 liquid antacids. Aliment Pharmacol Ther 2000; 14(4): 421–5PubMedCrossRef Temple ME, Nahata MC. Comparative palatability of 22 liquid antacids. Aliment Pharmacol Ther 2000; 14(4): 421–5PubMedCrossRef
14.
Zurück zum Zitat Bahal-O’Mara N, Force RW, Nahata MC. Palatability of 14 over-the-counter antacids. Am Pharm 1994; NS34 (1): 31–5 Bahal-O’Mara N, Force RW, Nahata MC. Palatability of 14 over-the-counter antacids. Am Pharm 1994; NS34 (1): 31–5
15.
Zurück zum Zitat Marriott C. The effect of flavour on acceptability of antacid tablets. J Clin Hosp Pharm 1983; 8(1): 69–73PubMed Marriott C. The effect of flavour on acceptability of antacid tablets. J Clin Hosp Pharm 1983; 8(1): 69–73PubMed
16.
Zurück zum Zitat Schneider RP, Roach AC. An antacid tasting: the relative palatability of 19 liquid antacids. South Med J 1976; 69(10): 1312–3PubMedCrossRef Schneider RP, Roach AC. An antacid tasting: the relative palatability of 19 liquid antacids. South Med J 1976; 69(10): 1312–3PubMedCrossRef
17.
Zurück zum Zitat Prodi DA, Drzyna D, Forabosco P, et al. Bitter taste study in a Sardinian genetic isolate supports the association of phenylthiocarbamide sensitivity to the TAS2R38 bitter receptor gene. Chem Senses 2004; 29(8): 697–702PubMedCrossRef Prodi DA, Drzyna D, Forabosco P, et al. Bitter taste study in a Sardinian genetic isolate supports the association of phenylthiocarbamide sensitivity to the TAS2R38 bitter receptor gene. Chem Senses 2004; 29(8): 697–702PubMedCrossRef
18.
Zurück zum Zitat Kim U, Drzyna D. Genetics of individual differences in bitter taste perception: lessons from the PTC gene. Clin Genet 2005; 67(4): 275–280PubMedCrossRef Kim U, Drzyna D. Genetics of individual differences in bitter taste perception: lessons from the PTC gene. Clin Genet 2005; 67(4): 275–280PubMedCrossRef
19.
Zurück zum Zitat Zantac Product Information. GlaxoSmithKline, Research-Triangle Park, NC, USA. October 2004 Zantac Product Information. GlaxoSmithKline, Research-Triangle Park, NC, USA. October 2004
20.
Zurück zum Zitat Prevacid Product Information. TAP Pharmaceutical Products Inc., Lake Forest, IL, USA. 2004 Prevacid Product Information. TAP Pharmaceutical Products Inc., Lake Forest, IL, USA. 2004
21.
Zurück zum Zitat Pumfrey B, Baxter G. Patient administration and acceptability of the lansoprazole oro-dispersible tablet. Presented at the 12th United European Gastroenterology Week, 25–29 September 2004, Prague, Czech Republic. Wed-G-292. Gut 2004; 53Suppl. VI: A289 Pumfrey B, Baxter G. Patient administration and acceptability of the lansoprazole oro-dispersible tablet. Presented at the 12th United European Gastroenterology Week, 25–29 September 2004, Prague, Czech Republic. Wed-G-292. Gut 2004; 53Suppl. VI: A289
22.
Zurück zum Zitat Freston JW, Jackson RL, Huang B, et al. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs 2002; 62(8): 1173–84PubMedCrossRef Freston JW, Jackson RL, Huang B, et al. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs 2002; 62(8): 1173–84PubMedCrossRef
23.
Zurück zum Zitat Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000; 40: 52–62 Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000; 40: 52–62
24.
Zurück zum Zitat Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 529–39PubMedCrossRef Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 529–39PubMedCrossRef
25.
Zurück zum Zitat Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2RA therapy. The lansoprazole maintenance study group. Am J Gastroenterol 1996; 91: 1758–65PubMed Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2RA therapy. The lansoprazole maintenance study group. Am J Gastroenterol 1996; 91: 1758–65PubMed
26.
Zurück zum Zitat Savarino V, Mela GS, Zentilin P, et al. Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine. Fundam Clin Pharmacol 1996; 10(3): 304–8PubMedCrossRef Savarino V, Mela GS, Zentilin P, et al. Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine. Fundam Clin Pharmacol 1996; 10(3): 304–8PubMedCrossRef
27.
Zurück zum Zitat Savarino V, Mela GS, Zentilin P, et al. Once-daily bedtime dose of roxatidine and ranitidine in acute duodenal ulcer: a combined assessment of acid inhibitory activity and healing rate. Am J Ther 1995; 2(12): 949–53PubMedCrossRef Savarino V, Mela GS, Zentilin P, et al. Once-daily bedtime dose of roxatidine and ranitidine in acute duodenal ulcer: a combined assessment of acid inhibitory activity and healing rate. Am J Ther 1995; 2(12): 949–53PubMedCrossRef
28.
Zurück zum Zitat Nakashima M, Kanamaru M. Clinico-pharmacological evaluation of omeprazole, as a proton pump inhibitor, compared with H2-blockers. Nippon Rinsho 1992; 50(1): 60–7PubMed Nakashima M, Kanamaru M. Clinico-pharmacological evaluation of omeprazole, as a proton pump inhibitor, compared with H2-blockers. Nippon Rinsho 1992; 50(1): 60–7PubMed
29.
Zurück zum Zitat Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35Suppl. 4: S300–7PubMedCrossRef Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35Suppl. 4: S300–7PubMedCrossRef
30.
Zurück zum Zitat Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35Suppl. 4: S308–18PubMedCrossRef Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35Suppl. 4: S308–18PubMedCrossRef
31.
Zurück zum Zitat Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993; 69(6): 655–9PubMedCrossRef Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993; 69(6): 655–9PubMedCrossRef
32.
Zurück zum Zitat Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993; 123(1): 148–54PubMedCrossRef Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993; 123(1): 148–54PubMedCrossRef
33.
Zurück zum Zitat Karjoo M, Kane R. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolesc Med 1995; 149(3): 267–71PubMedCrossRef Karjoo M, Kane R. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolesc Med 1995; 149(3): 267–71PubMedCrossRef
34.
Zurück zum Zitat Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001; 15(9): 1397–402PubMedCrossRef Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001; 15(9): 1397–402PubMedCrossRef
Metadaten
Titel
Taste Comparisons for Lansoprazole Strawberry-Flavoured Delayed-Release Orally Disintegrating Tablet and Ranitidine Peppermint-Flavoured Syrup in Children
verfasst von
Dr Vasundhara Tolia
Cong Han
Janine D. North
Fouad Amer
Publikationsdatum
01.05.2005
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 5/2005
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200525050-00001

Weitere Artikel der Ausgabe 5/2005

Clinical Drug Investigation 5/2005 Zur Ausgabe